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Abstract Medication overuse headache (MOH) is a daily
or almost-daily type of headache that results from the
chronicization, usually migraine or tension-type headache,
as a consequence of the progressive increase of intake of
symptomatic drugs. MOH is now the third most frequent
type of headache and affects a percentage of 1–1.4% of the
general population. The currently available data on the
impact of chronic headache associated with analgesic
overuse in specialist headache centres confirm, beyond
doubt, the existence of a serious health problem. Limited
amount of data exists on the burden and impact of MOH in
Latin American Countries. In this review, we summarise
the reliable information from the literature on the epide-
miological impact of MOH.
Keywords Drug-induced headache 
Medication overuse headache  Epidemiological impact 
Prevalence  Latin American countries
Introduction
Inappropriate use of acute headache medications by
patients with frequent migraine or tension-type headache
may contribute to the development of a chronic, daily (or
almost daily) headache that is induced and maintained by
the use of the painkilling drugs. This very aggressive and
disabling type of headache, now labelled medication
overuse headache (MOH), is a largely under-diagnosed
health condition, although it may affect 1–1.4% of the
general population [1–6].
The clinical complexity of MOH, formerly known by
other names—such as drug-induced headache, painkiller
headache, transformed migraine—or included in the group
of chronic daily headache (CDH) [7], has probably con-
tributed to difficulties in defining precise and widely
accepted diagnostic criteria for the condition. Indeed, over
the years different sets of diagnostic criteria have been
proposed and the experts in the field have only recently
reached a general consensus, which will probably favour
the acquisition of the necessary information on this dis-
abling disorder.
In this short paper, we discuss relevant epidemiological
data available on MOH, focusing on the information
regarding this condition in Latin American (LA) countries,
as a preparatory initiative to a project funded by the
COMOESTAS Consortium: C. Tassorelli (Project Manager),
G. Sances, G. Sandrini, F. Blandini, P. Rossi (IRCCS ‘‘Neurological
Institute C. Mondino’’ Foundation, University Centre for Headache
and Adaptive Disorders, Pavia), R. Jensen (Region Hovedstaden,
Glostrup Amtssygehuset), M. Lainez (Fundacio´n de la Comunidad
Valenciana para la Investigacio´n Biome´dica, la Docencia y la
Cooperacio´n Internacional y para el Desarrollo del Hospital Clı´nico
Universitario de Valencia—Spain), D. Mueller
(Universitaetsklinikum Essen), J. Leston, M.T. Goicoichea
(Fundacion para la Lucha contra las Enfermedades Neurologicas de la
Infanzia, Buenos Aires—Argentina), R. Fadic (Pontificia Universidad
Catolica de Chile, Santiago—Chile).
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European Commission and aimed at improving collabora-
tion and flow of information between Europe and Latin
America (COMOESTAS Project—EC contract number
215366 (COMOESTAS) FP7—Thematic priority ICT,
www.comoestas-project.eu).
Methods: search strategy and selection criteria
Data used for this review were extracted from the authors’
files and completed with data obtained from scientific
databases (i.e., PubMed or EMBASE) using the search
terms ‘‘medication overuse headache’’, ‘‘drug-induced
headache’’ or ‘‘chronic daily headache’’. Articles and
citations were selected on the basis of their scientific
validity, historical value, importance, relevance, and ease
of access. All indexed papers in English, German and
Spanish were included.
More than 140 articles in the above languages, pub-
lished in the past three decades in indexed journals were
identified. Of these, nearly 50 were included in the evalu-
ation. Articles were excluded if they were not considered
representative of the problem (single case reports, personal
opinions of single researchers, MOH was not the main
topic, etc.) or did not add important information or, again,
had been already analysed in reviews included in this
report.
MOH: the history
The clinical features of drug-induced headache were first
described in 1951 in relation to excessively frequent or
daily use of ergotamine [8]. Subsequently, the same
authors described improvement after ergotamine with-
drawal in 52 patients who had developed daily headache
following daily intake of ergotamine [9]. As from 1970s,
drug-induced headache was also described in patients using
analgesics and other compounds [10]. There is now sub-
stantial evidence that all drugs used for the treatment of
headache can cause MOH in patients with primary head-
ache disorders [10]. The pattern of use of the drugs that can
lead to MOH varies substantially from country to country
and is influenced by cultural factors. In many patients, it is
difficult to identify a single causal substance, since 90% of
patients take more than one compound at a time and each
of the single drug may, in theory, induce headache.
Many terms have been used to describe MOH; in 1988
the condition was defined ‘‘drug-induced headache’’ by the
International Headache Society [11]. This term, however,
was criticized since several drugs, other than painkillers,
can cause headache, even after a single dose, (nitrates, for
example). In addition, it has been questioned whether
headache can be primarily drug-induced [12]. Therefore,
the headache associated with the use of symptomatic drugs
was classified under the heading ‘‘Headache induced by
chronic substance use or exposure’’—to distinguish it from
the group of headaches induced by the acute use of drugs—
and included only two subtypes: headache induced by
ergotamine and headache associated with analgesics.
Studies conducted in the subsequent years, along with
availability of new symptomatic drugs, suggested the need
for a further revision of both the name and the diagnostic
criteria [13–15]. In 2004, the term ‘‘medication overuse
headache’’ was finally introduced into the second edition of
the International Headache Society’s Classification (Inter-
national Classification of Headache Disorders—II edition,
ICHD-II), also with the aim of emphasising excessive drug
intake as the basis of this form of headache [16]. In ICHD-
II, MOH is classified amongst the secondary headache,
within group 8: ‘‘Headache Attributed to a Substance or its
Withdrawal’’. Together, the 2004 classification [16] and
the two subsequent revisions of the diagnostic criteria for
MOH [17, 18] refine and extend the definition of this
condition on the basis of both its chronicity (headache on
more than 15 days/month for more than three months) and
the different types of drugs overused, thereby identifying
main types of MOH. In the case of ergotamine, triptans,
opioids and combination medications in particular, intake
on C10 days/month for [3 months is required, whereas
simple analgesics are considered overused when they are
taken on C15 days/month for [3 months (Table 1).
The epidemiological impact
MOH is a largely under-diagnosed health condition, but its
prevalence is increasing worldwide. Indeed, it is now the
third most frequent type of headache [10, 19].
According to epidemiological surveys performed in the
‘80s, between 1 and 3% of the general population take
analgesics on a daily basis, and up to 7% take them at least
once a week [20, 21]. Cross-sectional, population-based
and epidemiological studies in Europe and Asia indicate
that the prevalence of chronic headache associated with
medication overuse is about 1–1.4% in the general popu-
lation [1–6], with the prevalence peaking in women in their
50s. In this age range, indeed, 5% of women meet the
diagnostic criteria for MOH [3, 22]. A meta-analysis of 29
studies involving 2,612 patients with chronic headache and
analgesic overuse [23] confirmed the females predomi-
nance (F/M ratio: 3.5/1) and reported, in these patients, the
simultaneous use of an average of between 2.5 and 5.8
(range 1–14) different pharmacological agents. The mean
duration of primary headache at the time of diagnosis was
20.4 years, the mean duration of drug overuse was
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10.3 years, and the mean duration of daily headache
([15 days per month) was 5.9 years.
It is worth noting that the vast majority of these epide-
miological studies investigated chronic headache following
the overuse of analgesics or ergots diagnosed according to
the International Headache Society’s 1988 criteria [11]
and, in part, the revised criteria of Silberstein et al. [15, 24].
Therefore, data from these studies must be interpreted
cautiously, since they were conducted prior to the devel-
opment of the ICHD-II criteria, and it is not possible to
ascertain whether all the cases described really were MOH
(improvement within 2 months of discontinuation of the
overused medication now being required for a definite
diagnosis of MOH).
The situation will probably become clearer over the next
years as a result of application of the International Head-
ache Classification diagnostic criteria published in 2004
and alternative framing of data on the basis of the ‘‘new
appendix criteria’’ for the diagnosis of MOH, which, pro-
posed for research purposes, no longer require the
headache to improve after withdrawal [18].
Having outlined these premises, the currently available
data on the impact of chronic headache associated with
analgesic overuse in specialist headache centres confirm,
beyond doubt, the existence of a serious health problem. In
US specialist headache clinics, 60–80% of patients who
presented with CDH used analgesics on a daily or near-
daily basis [25–27]. More recently, a retrospective study
conducted in a large, tertiary care headache centre in the
United States (US) showed that the relative frequency of
probable MOH in this setting had remained remarkably
stable over the past 15 years [28], varying from 64% of all
cases seen in the centre in 1990 to 59.3% in 2005. At
variance with these findings, in European headache centres,
only 5–10% of patients presented with drug-induced
headache [29–31]. MOH may also be a high-impact disease
in general practice, as suggested by the results of a survey
of 174 general practitioners in the US, which showed that
chronic headache with overuse of symptomatic drugs is the
third most common form of headache [32]. There is
increasing evidence that the overuse of analgesics leading
to MOH is a major epidemiological issue not only in
Europe and North America, but also, more and more, in
Asian countries, too; indeed, the prevalence of MOH in
China and Taiwan is the same as that recorded in Europe
[1, 2, 5, 21, 33, 34].
MOH in Latin American countries
Unfortunately, the epidemiological impact of MOH in LA
countries is little known.
Indeed, some studies aiming at determining the preva-
lence of CDH have been conducted in Latin American [35,
36]. These studies point to a prevalence of CDH in Brazil
that is higher than the prevalence recorded in countries
outside of Latin America. However, it must be noted that
these studies were about CDH, but did not take into
account the actual epidemiological impact of MOH.
Indirect information can be derived by the study of Morillo
et al. [37] where the authors describe the clinical character-
istics and pattern of medication use of migraineurs in 12 LA
urban communities and report a total of 13% patients using
symptomatic medication on at least 16 days per month.
Owing to this substantial lack of published data on the
impact of MOH in LA countries, we planned a pilot study
Table 1 Medication overuse
headache: its subtypes and
diagnostic criteria [16–18]
a Removed in latest revision
[18]
8.2 Medication overuse headache (Previously used terms: rebound headache, drug-induced headache,
medication-misuse headache)
Subtypes
8.2.1 Ergotamine overuse headache
8.2.2 Triptan-overuse headache
8.2.3 Analgesic overuse headache
8.2.4 Opioid overuse headache
8.2.5 Combination analgesic overuse headache
8.2.6 Medication overuse headache attributed to combination of acute medications
8.2.7 Headache attributed to other medication overuse
8.2.8 Probable medication overuse headache
Diagnostic criteria:
A Headache present on [15 days/month fulfilling criteria C and Da
B Regular overuse for [3 months of 1 or more drugs that can be taken for acute and/or symptomatic
treatment of headache.
C Headache has developed or markedly worsened during medication overuse.
D Headache resolves or reverts to its previous pattern within 2 months after discontinuation of overused
medicationa
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in collaboration with our LA partners (Argentina and
Chile). The aim of this study was to estimate the impact of
MOH in specialised headache centres. To this end, we
developed a clinical report form for the diagnosis of MOH
and the collection of relevant data from patients. This
report form was administered to 100 consecutive patients
referred to the Headache Centre of the Fleni Institute in
Buenos Aires (Argentina) and to the Headache Centre of
the Pontificia University of Santiago (Chile). According to
the data supplied by our partners (Fadic R and Goicoichea
MT, personal observations), in LA countries MOH
accounts for between 55% (the Chilean centre) and 70%
(the Argentinean centre) of headache patients seen in
specialist centres. These findings, which will be better
analysed by the COMOESTAS consortium, confirm the
higher prevalence of MOH in subjects attending headache
clinics; moreover, this result is similar to that found in
tertiary headache clinics in US [28]. Of course, as in other
studies, MOH patients who seek specialist care are likely to
differ from MOH sufferers in the general population.
MOH has changed over time
The acute treatment of migraine has changed substantially
over the past 15 years, following the marketing of the
triptans, and so, too, has the type of MOH. Four studies
[30, 38–40] investigating the frequency of the headache
associated with the use of various drugs were performed
prior to the publication of the ICHD-2 diagnostic criteria
for MOH. In a US study, combination analgesics contain-
ing butalbital (a short-acting barbiturate), caffeine, and
aspirin with or without codeine emerged as the medications
most likely to cause MOH [39]. Until the mid 1990s,
combination analgesics with codeine or caffeine, or ergots
combined with codeine were the most common headache
therapies in many European countries [30, 38, 40].
However, the introduction of the triptans and the recent
withdrawal of ergots from some markets (e.g., Germany) is
changing this picture. In fact, since 1994, clinical reports
have suggested that the triptan overuse, too, may lead to the
development of MOH [41, 42]. Sumatriptan-induced MOH
was first recorded in patients who had previously overused
ergotamine [41, 43]. MOH was later reported [44] in
patients using naratriptan, zolmitriptan, or rizatriptan.
Typically, triptan-induced MOH appears 1 year after a
drug has been commercialised [44]. Triptan-induced MOH
shows more migrainous features, it develops more rapidly
than that associated with other classes of symptomatic
drugs, and is associated with a lower mean critical monthly
dosage [45]. Increasing body of evidence suggests that all
the available triptans can cause MOH [45, 46] and reports
on MOH induced by the newer triptans (eletriptan,
frovatriptan, almotriptan) will probably appear in the next
future.
A study based on the prescription register in Denmark
revealed that the prevalence of sumatriptan use in the
Danish population, in 1995, was 0.78%. Of these users, up
to 5% overused sumatriptan on a daily basis [47]. Evers
and colleagues found that 4.7% of 320 sumatriptan users
overused the drug by taking it at least every other day [48].
A recent population-based study in France revealed that
triptans are used in a low percentage (7.5%) of migraine
patients, but in a definitely higher proportion (25%) of
patients with CDH [49]. This latter observation suggest a
potential causal relationship between triptan misuse and
development of daily chronic headache, although future
studies are needed to address this issue.
MOH in children and adolescents
Several studies have addressed the prevalence of chronic
headache in early adolescence and even in childhood [50,
51]. Hering-Hanit and Gadoth [51] reported daily or near-
daily headache related to excessive consumption of caf-
feine in a group of 36 children and adolescents aged from 6
to 18 years; in this study, the mean age of the subjects was
9.2 years, with a mean duration of headache of 1.8 years;
thus, indicating that overuse may also begin very early.
Adolescents with analgesic-induced headache responding
to withdrawal treatment have also been reported [52];
however, conclusive data are missing on the real dimension
of the problem. The scarce data available from the litera-
ture seem to suggest that MOH in children and adolescents
may be less frequent than in adults. In one population-
based study conducted in Taiwan, the authors reported a
prevalence of 1.5% of CDH in a population of adolescents
(12–14 years of age) and MOH was present only in 1/5 of
these subjects [53]. Furthermore, a study from Canada,
conducted in a general paediatric neurology ambulatory
practice, showed that daily chronic headache prevalence
was 3% in a group of 1,669 children seen because of
headache. In this small subset of children suffering from
chronic headache, medication overuse was present in 50%
of cases [54].
Conclusion
The data illustrated confirm that MOH is a chronic disorder
and major health problem that affects a huge number of
subjects, including youngsters. Although scientific data is
limited, MOH, on account of its clinical characteristics, is
clearly a cause of disability and, if not adequately treated,
of co-morbidity due to the excessive intake of drugs.
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MOH can be treated through withdrawal of the overused
drug(s) and adopting specific approaches that focus on the
development of a close doctor–patient relationship in the
post-withdrawal period.
Conflict of interest None.
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